Anti-trka antibody or antigen-binding fragment thereof, preparation method thereof, and application thereof
AssigneeXiyuan Anjian Medicine (Shanghai) Co., Ltd
InventorsXiaohui Yuan, Guoyong Wang, Yujiao Liu, Donghong Zheng
Life of this patent
Estimating the term…
Abstract
The present invention provides an anti-TrkA antibody or an antigen-binding fragment thereof, a preparation method, and an application thereof. The present invention also provides an isolated polynucleotide encoding the anti-TrkA antibody or the antigen-binding fragments thereof, and a vector comprising the isolated polynucleotide. The present invention also provides a use of the antibody or the antigen-binding fragment thereof in the preparation of a drug for treating pain.
Claims5
An antibody or antigen-binding fragment thereof capable of specifically binding to TrkA, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region VH and a light chain variable region VL:
- the VH of the antibody or antigen-binding fragment thereof comprises:
- VH CDR1 as shown in SEQ ID NO:
- 1, VH CDR2 as shown in SEQ ID NO:
- 2, and VH CDR3 as shown in SEQ ID NO:
- 3;
- and the VL of the antibody or antigen-binding fragment thereof comprises:
- VL CDR1 as shown in SEQ ID NO:
- 25, VL CDR2 as shown in SEQ ID NO:
- 26, and VL CDR3 as shown in SEQ ID NO:
- 27;
- or
- the VH of the antibody or antigen-binding fragment thereof comprises:
- VH CDR1 as shown in SEQ ID NO:
- 4, VH CDR2 as shown in SEQ ID NO:
- 5, and VH CDR3 as shown in SEQ ID NO:
- 6;
- and the VL of the antibody or antigen-binding fragment thereof comprises:
- VL CDR1 as shown in SEQ ID NO:
- 28, VL CDR2 as shown in SEQ ID NO:
- 29, and VL CDR3 as shown in SEQ ID NO:
- 30;
- or
- the VH of the antibody or antigen-binding fragment thereof comprises:
- VH CDR1 as shown in SEQ ID NO:
- 7, VH CDR2 as shown in SEQ ID NO:
- 8, and VH CDR3 as shown in SEQ ID NO:
- 9;
- and the VL of the antibody or antigen-binding fragment thereof comprises:
- VL CDR1 as shown in SEQ ID NO:
- 31, VL CDR2 as shown in SEQ ID NO:
- 32, and VL CDR3 as shown in SEQ ID NO:
- 33;
- or
- the VH of the antibody or antigen-binding fragment thereof comprises:
- VH CDR1 as shown in SEQ ID NO:
- 10, VH CDR2 as shown in SEQ ID NO:
- 11, and VH CDR3 as shown in SEQ ID NO:
- 12;
- and the VL of the antibody or antigen-binding fragment thereof comprises:
- VL CDR1 as shown in SEQ ID NO:
- 34, VL CDR2 as shown in SEQ ID NO:
- 35, and VL CDR3 as shown in SEQ ID NO:
- 36;
- or
- the VH of the antibody or antigen-binding fragment thereof comprises:
- VH CDR1 as shown in SEQ ID NO:13, VH CDR2 as shown in SEQ ID NO:14 and VH CDR3 as shown in SEQ ID NO:
- 15, and the VL of the antibody or antigen-binding fragment thereof comprises:
- VL CDR1 as shown in SEQ ID NO:
- 37, VL CDR2 as shown in SEQ ID NO:
- 38, and VL CDR3 as shown in SEQ ID NO:
- 39;
- or
- the VH of the antibody or antigen-binding fragment thereof comprises:
- VH CDR1 as shown in SEQ ID NO:16, VH CDR2 as shown in SEQ ID NO:17 and VH CDR3 as shown in SEQ ID NO:
- 18, and the VL of the antibody or antigen-binding fragment thereof comprises:
- VL CDR1 as shown in SEQ ID NO:
- 40, VL CDR2 as shown in SEQ ID NO:
- 41, and VL CDR3 as shown in SEQ ID NO:
- 42;
- or
- the VH of the antibody or antigen-binding fragment thereof comprises:
- VH CDR1 as shown in SEQ ID NO:19, VH CDR2 as shown in SEQ ID NO:20 and VH CDR3 as shown in SEQ ID NO:
- 21, and the VL of the antibody or antigen-binding fragment thereof comprises:
- VL CDR1 as shown in SEQ ID NO:
- 43, VL CDR2 as shown in SEQ ID NO:
- 44, and VL CDR3 as shown in SEQ ID NO:
- 45;
- or
- the VH of the antibody or antigen-binding fragment thereof comprises:
- VH CDR1 as shown in SEQ ID NO:
- 22, VH CDR2 as shown in SEQ ID NO:
- 23, and VH CDR3 as shown in SEQ ID NO:
- 24, and the VL of the antibody or antigen-binding fragment thereof comprises:
- VL CDR1 as shown in SEQ ID NO:
- 46, VL CDR2 as shown in SEQ ID NO:
- 47, and VL CDR3 as shown in SEQ ID NO:
- 48.
Dependencies are inferred from the claim text.